Search

Displaying results 641 - 650 of 10000 in total
  1. Drug

    Imlunestrant

    go.drugbank.com/drugs/DB19043
    ApprovedInvestigational

    progression on at least one line of endocrine therapy. … The FDA approved imlunestrant on September 25, 2025 [L54051] as a treatment for estrogen receptor (ER)-positive, HER2-negative, estrogen receptor 1 (ESR1)-mutated advanced or metastatic breast cancer with

  2. Drug

    Lacosamide

    go.drugbank.com/drugs/DB06218
    ApprovedInvestigational

    Lacosamide is an antiepileptic drug used to treat seizures. As a chiral functionalized amino acid, it works by blocking slowly inactivating components of voltage-gated sodium currents. … [A262681] Lacosamide was first approved by the European Commission in August 2008 and was later approved by the FDA in October 2008.

    Synonyms: (+)-(2R)-2-(ACETYLAMINO)-N-BENZYL-3-METHOXYPROPANAMIDE, (R)-2-acetamido-N-benzyl-3- methoxypropionamideProducts: LACOSAMIDE EG, LASOMID IN
  3. Drug

    Avobenzone

    go.drugbank.com/drugs/DB09495
    ApprovedInvestigational

    Avobenzone is very sensitive to light, to increase its stability and duration of action, photostablizers are added in the sunscreen product. Avobenzone has an absorption maximum of 357 nm. … It is included in many commercially available sunscreens which are used as wide spectrum sunscreens.

    Mixtures: Bullet Line, Bullet LineCategories: Compounds used in a research, industrial, or household setting
  4. Drug

    Tadalafil

    go.drugbank.com/drugs/DB00820
    ApprovedInvestigational

    Tadalafil is a selective phosphodiesterase-5 inhibitor that is used in the treatment of erectile dysfunction (ED), pulmonary arterial hypertension (PAH), and benign prostatic hypertrophy. … In contrast to other PDE5 inhibitors like [sildenafil], tadalafil has greater selectivity for PDE5 and a longer half-life which has made it a more suitable option for chronic once-daily dosing in the treatment

    Categories: Drugs Used in Erectile Dysfunction, Drugs Used in Benign Prostatic HypertrophyProducts: N/a, TADALAFIL EG
  5. Drug

    Acyclovir

    go.drugbank.com/drugs/DB00787
    ApprovedInvestigational

    [L7303,L7315,L7318,L7321,L7324,L7327] Acyclovir is generally used first line in the treatment of these viruses and some products are indicated for patients as young as 6 years old. … [L7321] Acyclovir was granted FDA approval on 29 March 1982.[L7318]

    Mixtures: VIROBIS LProducts: ACICLOVIR EG, KLOVİREKS-L 250 MG LİYOFİLİZE ENJEKTABL TOZ
  6. Drug

    Ibuprofen

    go.drugbank.com/drugs/DB01050
    ApprovedInvestigational

    [A39076] On the available products, ibuprofen is administered as a racemic mixture. … [A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.

    Mixtures: ADVIL® CONTRA LOS SÍNTOMAS DE LA GRIPA MULTISINTOMAS, ADVIL® CONTRA LOS SÍNTOMAS DE LA GRIPA MULTISINTOMASProducts: Lab Safety Supply Ibuprofen, IBUPROFENE EG
  7. Drug

    Pixantrone

    go.drugbank.com/drugs/DB06193
    ApprovedWithdrawn

    Pixantrone dimaleate, administered intravenously, was designed by Cell Therapeutics Incorporated as an alternative second line therapy in refractory or relapsed NHL. … Pixantrone was designed to treat relapsed or refractory aggressive non-Hodgkin's lymphoma(NHL) in patients who have failed two prior lines of therapy. [2] For patients suffering from NHL, first line therapies

  8. Drug

    Bortezomib

    go.drugbank.com/drugs/DB00188
    ApprovedInvestigational

    [A204083] The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest and … [L14180] However, multiple mechanisms may be involved in the anticancer activity of bortezomib.[A204083] Bortezomib was first synthesized in 1995.

    Synonyms: N-[(1R)-1-(DIHYDROXYBORYL)-3-methylbutyl]-N-(pyrazin-2-ylcarbonyl)-L-phenylalaninamideCategories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index
  9. Drug

    Octisalate

    go.drugbank.com/drugs/DB11062
    Approved

    Octyl salicylate is an oil soluble chemical sunscreen agent that absorbs UVB radiation. It does not protect against UVA. Octyl salicylate is used to augment the UVB protection in a sunscreen. … Salicylates are weak UVB absorbers and they are generally used in combination with other UV filters. Octyl salicylate appears to have a good safety profile.

    Mixtures: Bullet Line, Bullet LineCategories: Compounds used in a research, industrial, or household setting
  10. Drug

    Esomeprazole

    go.drugbank.com/drugs/DB00736
    ApprovedInvestigational

    [A177571] Rapid discontinuation of PPIs such as esomeprazole may cause a rebound effect and a short term increase in hypersecretion. … [A177577, A177580] Due to their good safety profile and as several PPIs are available over the counter without a prescription, their current use in North America is widespread.

    International brands: ES-ODProducts: E-SOME, ESOMEPRAZOLO EG